UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 15, 2014
AMICUS THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-33497 |
|
71-0869350 |
|
(State or other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
1 Cedar Brook Drive, Cranbury, NJ |
|
08512 |
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (609) 662-2000
(Former name or former address if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On October 15, 2014, the Board of Directors of Amicus Therapeutics, Inc. (the “Company”) approved an amendment to the Company’s Cash Deferral Plan (the “Plan”) to provide that the election of each participant to defer compensation under the Plan will terminate at the end of each plan year instead of continuing in effect until amended by such participant (the “Amendment”). Accordingly, pursuant to the Amendment, each participant will be required to file a new election for each year in which the participant wishes to defer receipt of such participant’s compensation. Additionally, the Amendment provided for other administrative changes to the Plan.
The foregoing summary of the Amendment is qualified in its entirety by reference to Amendment #1 to the Cash Deferral Plan, which is included as Exhibit 10.1 to this current report on Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
|
Exhibit No. |
|
Description |
|
10.1 |
|
Amendment #1 to the Cash Deferral Plan |
|
|
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
AMICUS THERAPEUTICS, INC. | |
|
|
| |
|
Date: October 16, 2014 |
By: |
/s/ WILLIAM D. BAIRD III |
|
|
Name: |
William D. Baird III |
|
|
Title: |
Chief Financial Officer |